Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.62 |
| ▸ | PTP4A3 | O75365 | 3/20 | 0.59 |
| ▸ | NAT1 | P18440 | 6/20 | 0.54 |
| ▸ | MYC | P01106 | 1/20 | 0.54 |
| ▸ | MAX | P61244 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.51 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13846835 | 1.00 | PIM1 (0.62) | PIM1PTP4A3NAT1MYCMAX | |
| SCHEMBL13499576 | 0.90 | PTP4A3 (0.72) | PIM1PTP4A3NAT1MYCMAX | |
| SCHEMBL14661290 | 0.90 | PIM1 (0.70) | PIM1PTP4A3NAT1MYCMAX | |
| SCHEMBL14661291 | 0.90 | PIM1 (0.70) | PIM1PTP4A3NAT1MYCMAX | |
| SCHEMBL13499565 | 0.90 | PIM1 (0.70) | PIM1PTP4A3NAT1MYCMAX | |
| SCHEMBL18102853 | 0.83 | NAT1 (0.62) | PIM1PTP4A3NAT1MYCMAX | |
| SCHEMBL18102933 | 0.83 | NAT1 (0.62) | PIM1PTP4A3NAT1MYCMAX | |
| SCHEMBL13499561 | 0.81 | PIM1 (0.74) | PIM1PTP4A3NAT1MYCMAX | |
| SCHEMBL13499574 | 0.80 | NAT1 (0.64) | PIM1PTP4A3NAT1CA2CISD1 | |
| SCHEMBL13499578 | 0.77 | PIM1 (0.62) | PIM1PTP4A3NAT1MYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736894-B1 | METHOD FOR PRODUCING BENZO[B] THIOPHENE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-9206169-B2 | Method for producing benzo[b]thiophene compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140187782-A1 | METHOD FOR PRODUCING BENZO[B]THIOPHENE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| EP-2736894-A1 | METHOD FOR PRODUCING BENZO[B]THIOPHENE COMPOUND | Otsuka Pharmaceutical Co., Limited (JP) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013015456-A1 | METHOD FOR PRODUCING BENZO[B]THIOPHENE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187782-A1 | METHOD FOR PRODUCING BENZO[B]THIOPHENE COMPOUND | H1-4, H1-0, RB1 | PIM1 480/4885PTP4A3 903/4885NAT1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.